Cervical Cancer Clinical Trials

221 recruiting

Cervical Cancer Trials at a Glance

297 actively recruiting trials for cervical cancer are listed on ClinicalTrialsFinder across 6 cities in 62 countries. The largest study group is Not Applicable with 100 trials, with the heaviest enrollment activity in Houston, New York, and Hangzhou. Lead sponsors running cervical cancer studies include M.D. Anderson Cancer Center, Chongqing University Cancer Hospital, and Fondazione Policlinico Universitario Agostino Gemelli IRCCS.

Browse cervical cancer trials by phase

Treatments under study

About Cervical Cancer Clinical Trials

Looking for clinical trials for Cervical Cancer? There are currently 221 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Cervical Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Cervical Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 297 trials

Recruiting

DESTINY-PANTUMOUR04

Liver CancerEsophageal CancerPancreatic Cancer+24 more
AstraZeneca100 enrolled17 locationsNCT07124000
Recruiting
Phase 3

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

Cervical Cancer
Merck Sharp & Dohme LLC1,023 enrolled87 locationsNCT07216703
Recruiting
Phase 3

A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

Cervical Cancer
Merck Sharp & Dohme LLC686 enrolled240 locationsNCT06459180
Recruiting
Phase 1

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

Breast CancerCervical CancerColon Cancer+4 more
Orano Med LLC48 enrolled4 locationsNCT05283330
Recruiting
Phase 3

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

Stage IIIA Cervical Cancer FIGO 2018Stage IIIB Cervical Cancer FIGO 2018Locally Advanced Cervical Adenocarcinoma+5 more
National Cancer Institute (NCI)336 enrolled222 locationsNCT07061977
Recruiting
Phase 4

Kupewa: Optimizing Implementation Strategies for Cervical Cancer Prevention

Cervical Cancer Prevention
New York University7,000 enrolled1 locationNCT07015957
Recruiting
Phase 3

Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)

Locally Advanced Cervical Cancer
AstraZeneca800 enrolled204 locationsNCT06079671
Recruiting
Not Applicable

Using Virtual Reality Technology to Improve Patient Experience and Quality of Care During Brachytherapy

Endocervical Cancer
University of Arkansas20 enrolled1 locationNCT05440760
Recruiting
Phase 1

A Clinical Study of Nanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer

CachexiaLocally Advanced Cervical Cancer
Second Xiangya Hospital of Central South University88 enrolled1 locationNCT07338487
Recruiting
Phase 1Phase 2

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

Cervical CancerMelanomaBladder Cancer+6 more
University of Arizona30 enrolled2 locationsNCT06814496
Recruiting
Not Applicable

Early Pelvic Floor Physical Therapy for Women Undergoing Pelvic Radiation for Gynecologic Malignancies

Cervical CancerRadiation Therapy ComplicationPelvic Floor Disorders
University of Cincinnati28 enrolled1 locationNCT07447895
Recruiting
Phase 2

PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer

Cervical CancerRecurrent Cervical CarcinomaHPV-Related Malignancy+2 more
Precigen, Inc24 enrolled3 locationsNCT06157151
Recruiting
Not Applicable

Feasibility of HPV Self-Collection Kits for Cervical Cancer Screening

Cervical CancerHPV Infection
Washington University School of Medicine100 enrolled1 locationNCT07453459
Recruiting
Phase 2

A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant Tumors

Ovarian CancerCervical Cancer
Shanghai Henlius Biotech190 enrolled1 locationNCT06769152
Recruiting
Phase 4

Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer

Cervical Cancer
Pfizer100 enrolled93 locationsNCT06952660
Recruiting
Not Applicable

Digital Telecytology for Triage of HPV-Positive Women in Cameroon

Human Papillomavirus InfectionCervical Cancer Screening MethodsCervical Intraepithelial Neoplasia Grade 2 (CIN2)
University Hospital, Geneva1,800 enrolled2 locationsNCT07550010
Recruiting

Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer

Ovarian CancerCervical CancerEndometrial Cancer+3 more
Mayo Clinic3,110 enrolled24 locationsNCT05051722
Recruiting

The Impact Of A Patient Support Community On Patients With Neuroendocrine Cervical Cancer: NECC Peer Support

Neuroendocrine Cervical CancerPatient Support
M.D. Anderson Cancer Center25 enrolled1 locationNCT07532954
Recruiting
Phase 1Phase 2

Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments

Ovarian CancerPancreatic CarcinomaAdvanced Solid Tumors+1 more
Evopoint Biosciences Inc.350 enrolled24 locationsNCT06799637
Recruiting
Phase 3

A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer

Advanced Cervical Cancer
Shanghai Shengdi Pharmaceutical Co., Ltd720 enrolled1 locationNCT07168200